Lysophosphatidic acid: an ovarian cancer marker

Objective: To determine whether lysophosphatidic acid (LPA) can serve as an ovarian cancer marker, we compared plasma LPA levels in ovarian cancer patients, in women with no ovarian pathology, and in women with benign ovarian tumors. We determined the optimal plasma LPA level Cutoff value and correlated clinicopathological parameters with plasma LPA levels. Method: Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 133 patients (60 patients with ovarian cancer, 43 women without ovarian pathologies and 30 patients with benign ovarian tumors) during a three-year period. Results: Patients with ovarian cancer had a significantly higher plasma LPA level (n = 60, median (med) 16.99 mu mol/l, range 4.53-43.21 mu mol/l) compared with controls with no ovarian pathology (n = 43, med 2.92 mu mol/l, range 0.94-22.93 mu mol/l) and patients with benign ovarian tumor (n = 30, med 7.73 mu mol/l, range 1.12-28.84 mu mol/l) (p < 0.00 1). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics (FIGO) stage and ovarian cancer histological type. Patients with endometrial ovarian cancer had significantly higher plasma LPA levels in comparison with other histological types of epithelial ovarian carcinoma. Conclusion: The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of disease.

Ovarian cancer; Lysophosphatidic acid; Marker

[1] Schwartz P.E., Taylor K.J.: “Is early detection of ovarian cancer possible?”. An. Med., 1995, 27, 519.

[2] Fishman D.A., Bozorgi K.: “The scientific basis of early detection of epithelial ovarian cancer: The National Ovarian Cancer Early Detection Program (NOCEDP)”. Cancer Treat Res., 2002, 107, 3.

[3] So J., Navari J., Wang F.O., Fishman D.A.: “Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8”. Gynecol. Oncol., 2004, 95, 314.

[4] Xiao Y.J., Schwarz B., Washington M., Kennedy A., Webster K., Belinson J., Xu Y.: “Electrospray ionization spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant versus nonmalignant ascitic fluids”. Anal. Biochem., 2001, 290, 302.

[5] Hu Y.L., Tee M.K., Goetzl E.J., Auersperg N., Mills G.B., Ferrara N. et al.: “Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells”. J. Natl. Cancer Inst., 2001, 93, 762.

[6] Lee Z., Swaby F.R., Liang Y., Yu S., Liu S., Lu K.H. et al.: “Lysophophatidic Acid Is a Major Regulator of Growth-Regulated Oncogene in Ovarian Cancer”. Cancer Research, 2006, 66, 2740.

[7] Wang P.,Wu X., Chen W., Liu J.,Wang X.: “The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms”. Gynecol. Oncol., 2007, 104, 714.

[8] Eder A.M., Sasagawa T., Mao M., Aoki J., Mills G.B.: “Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2”. Clin. Cancer Res., 2000, 6, 2482.

[9] Ozols R.F., Rubin S.C., Thomas G., Robboy S.: “Epithelial ovarian cancer”. In: Hoskins W.J., Perez C.A., Zouny R.C. (eds.). Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott-Raven Publishers. 1997, 958.

[10] WHO. WHO Handbook for reporting results of cancer treatment. Geneva (Switzerland), WHO, 1979.

[11] Sutphen R., Xu Y., Wilbanks D., Fiorica J., Grendys E.C. Jr., La Polla J.P. et al.: “Lysophospholipids are potential biomarkers of ovarian cancer”. Cancer Epidem., 2004, 13, 1185.

[12] Okita M., Gaudette D.C., Mills G.B., Holub B.J.: “Elevated levels and altered fatty acid composition of plasma lysophosphatidylicholine in ovarian cancer patients”. Int. J. Cancer, 1997, 71, 31.

[13] Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P. et al.: “Lysophosphatidic acid as a potential biomarker for ovarian and other Gynecologic Cancers”. JAMA, 1998, 280, 719.

[14] Sedláková I., Vávrová J., Tosˇner J., Hanousek L.: “Lysophosphatidic acid in ovarian cancer patients”. Cˇ eská Gynekologie, 2006, 71, 312.

[15] Baker D.L., Kortison P., Miller B., Riely C.A., Tolley B., Westermann A.M. et al.: “Plasma lysophosphatidic acid concentration and ovarian cancer”. JAMA, 2002, 287, 3081.

[16] So J., Wang F., Navari J., Fishman D.A.: “LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2)”. Gynecol. Oncol., 2005, 97, 870.